Trial
NCT03108495
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Iovance Biotherapeutics, Inc.
Collaborators
—
Condition
Cervical Carcinoma
Intervention
LN-145
Why stopped
After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-31